Merck Operating Income 2010-2022 | MRK

Merck annual/quarterly operating income history and growth rate from 2010 to 2022. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
  • Merck operating income for the quarter ending June 30, 2022 was $5.067B, a 198.76% increase year-over-year.
  • Merck operating income for the twelve months ending June 30, 2022 was $19.363B, a 429.62% increase year-over-year.
  • Merck annual operating income for 2021 was $13.199B, a 137.91% increase from 2020.
  • Merck annual operating income for 2020 was $5.548B, a 30% decline from 2019.
  • Merck annual operating income for 2019 was $7.926B, a 11.25% decline from 2018.
Merck Annual Operating Income
(Millions of US $)
2021 $13,199
2020 $5,548
2019 $7,926
2018 $8,931
2017 $6,797
2016 $5,499
2015 $7,547
2014 $6,683
2013 $7,665
2012 $9,877
2011 $8,976
2010 $3,355
2009 $4,021
Merck Quarterly Operating Income
(Millions of US $)
2022-06-30 $5,067
2022-03-31 $5,622
2021-12-31 $3,751
2021-09-30 $4,923
2021-06-30 $1,696
2021-03-31 $2,829
2020-12-31 $-3,376
2020-09-30 $2,507
2020-06-30 $2,436
2020-03-31 $3,981
2019-12-31 $-1,554
2019-09-30 $2,614
2019-06-30 $3,458
2019-03-31 $3,408
2018-12-31 $2,852
2018-09-30 $2,664
2018-06-30 $2,266
2018-03-31 $1,149
2017-12-31 $2,036
2017-09-30 $146
2017-06-30 $2,532
2017-03-31 $2,083
2016-12-31 $-991
2016-09-30 $3,070
2016-06-30 $1,657
2016-03-31 $1,763
2015-12-31 $1,952
2015-09-30 $2,340
2015-06-30 $1,737
2015-03-31 $1,518
2014-12-31 $1,526
2014-09-30 $1,700
2014-06-30 $1,404
2014-03-31 $2,053
2013-12-31 $1,897
2013-09-30 $2,465
2013-06-30 $1,485
2013-03-31 $1,818
2012-12-31 $1,964
2012-09-30 $2,370
2012-06-30 $2,785
2012-03-31 $2,758
2011-12-31 $1,995
2011-09-30 $2,376
2011-06-30 $2,406
2011-03-31 $2,199
2010-12-31 $-441
2010-09-30 $1,420
2010-06-30 $1,443
2010-03-31 $933
2009-12-31 $-234
2009-09-30 $1,640
2009-06-30 $1,421
2009-03-31 $1,194
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $218.318B $48.704B
Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $435.655B 16.59
Eli Lilly (LLY) United States $292.179B 37.05
AbbVie (ABBV) United States $249.673B 10.61
Pfizer (PFE) United States $245.989B 7.21
Novo Nordisk (NVO) Denmark $215.616B 28.44
Novartis AG (NVS) Switzerland $165.082B 12.17